BY MARKETWIRE
-
Citi sees difficult year ahead for Novo Nordisk
An effective tablet computer launch can well be among minority brilliant areas for Novo Nordisk in 2026, according to experts at the big financial institution.
-
Nordic finance firm boosts confidence in Genmab despite disappointing new data
Brand-new information for cancer cells medicine Epkinly dissatisfied capitalists and activated a decrease in Genmab’s share rate.
-
Novo Nordisk warns of a difficult 2026: Stock exchange warns of increased pressure on business outside the US
Novo Nordisk has actually shown that there is higher stress on worldwide markets than at first anticipated, creates significant financial institution Jefferies.
-
Novo Nordisk at its highest level since July after uplifting sales
Novo Nordisk’s supply has actually been progressively increasing at the start of 2026.
-
Goldman Sachs sees good momentum from Novo Nordisk’s Wegovy tablet
The United States financial investment financial institution approximates that Novo Nordisk’s Wegovy tablet computer is most likely to affect view in the short-term and add t…
-
Novo Nordisk’s Wegovy tablet is taking the US by storm: “It’s very encouraging”
Recently, a total amount of 20,371 prescriptions for brand-new clients were created for the Wegovy tablet computer, compared to 4,289 prescriptions the previous week.
-
Moderna in significant “detached” progress
Moderna is once more on top of the S&P index.
-
Novo closes at the highest level since Doustdar’s appointment
The Novo supply has actually normally varied hugely throughout the week.
-
Trump’s push for higher drug prices in Europe remains uncertain
Donald Trump states he pushed French Head of state Emmanuel Macron to increase a medication rate, however Macron’s workplace refutes the insurance claim on social media sites…
-
Johnson & Johnson’s Darzalex sales exceed expectations
The cancer cells medication Darzalex, where Genmab obtains aristocracies, produced sales of USD 3,903 m in the 4th quarter of the year.
